RxDoctor Payments Data

Osei Owusu, MD

Hematology & Oncology · Cleveland, OHNPI 1538184486

Payments from drug & device makers

$502in general payments, 2019–2025

Across 24 payments — averaging $20.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$137
  • Pfizer$55
  • Merck$51
  • Regeneron Healthcare Solutions, Inc.$39
  • Eisai Inc.$24
  • Coherus Oncology, Inc.$23
  • plus $173 from 10 others

What the payments were for

  • Food & beverage$47895%
  • Education$245%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$502 in reported general payments places this provider in the 20th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$68,104
Medicare patients
250
Services billed
667

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib57$899,896
RevlimidLenalidomide45$874,094
Lenalidomide49$730,294
ImbruvicaIbrutinib33$703,214
TagrissoOsimertinib Mesylate20$567,469
PomalystPomalidomide18$441,241
CalquenceAcalabrutinib Maleate35$419,519
BrukinsaZanubrutinib23$318,554
NinlaroIxazomib Citrate18$232,951
ErleadaApalutamide14$209,748
SprycelDasatinib16$154,991
Abiraterone Acetate49$149,710
VenclextaVenetoclax18$143,655
Imatinib Mesylate28$92,777
EliquisApixaban54$34,069

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$55$933,965111 claims
E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel$13$596,23134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →